

Special Issue

Antibiotic Resistance: One Health Issue

Message from the Guest Editors

Antimicrobial resistance has become increasingly evident and treated by leading global health organizations as one of the most relevant global health challenges of the 21st century. Some of the causes of failure in treating human infections include the indiscriminate and inappropriate use of these compounds, both in the human clinic and in animal production. Administration of subinhibitory concentrations can increase mutation rates, leading to intestinal bacterial population diversification and the selection of multiple drug resistance genes. Even more worrying is knowing that, currently, the consumption of antimicrobials by animals is twice as high as in humans, and most of these compounds are destined for animal production. Thus, we would like to invite researchers to publish their studies on this subject area, not only pointing out the problem of micro-organism resistance to antibiotics, but also bringing innovative solutions that can help us to slow down the growth of this problem that surrounds us

Guest Editors

Dr. Pedro Panzenhagen
Prof. Dr. Rafaela Gomes Ferrari
Prof. Dr. Carlos Adam Conte Júnior

Deadline for manuscript submissions

closed (28 February 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/162488

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)